Tens of thousands more women in England at an increased risk of breast cancer could now benefit from a proven risk-reducing drug on the NHS. Anastrozole, a drug commonly used in breast cancer treatment, has been licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) for preventive use. It is estimated that this drug could help prevent around 2,000 cases of breast cancer in England.
Anastrozole, which is off-patent, has been shown in trials to reduce the incidence of the disease in post-menopausal women at increased risk of breast cancer by almost 50%. Although it was recommended as a preventive option by the National Institute for Health and Care Excellence in 2017, the unlicensed use has led to low uptake.
Stay connected to UKNIP via Google News
ENJOYED THIS STORY? Choose UKNIP as a 'Preferred Source' on Google News for quick access to the news you value.
